Status: Recruiting
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)
Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: FemaleType: InterventionalSponsor: Elizabeth Stover, MD, PhDUpdated: Apr 21, 2026Locations: 3
Eligibility criteria
Participants must have histologically confirmed relapsed or refractory ovarian c... [+26]
Prior treatment with weekly paclitaxel in the recurrent setting. Prior dose-dens... [+17]